Adverum Biotechnologies (ADVM) announced it has notified sites that it plans to complete screening in ARTEMIS, its first pivotal Phase 3 trial evaluating Ixo-vec in wet age-related macular degeneration by September 30, seven months after initiation, because the company now expects full enrollment of at least 284 treatment-naive and treatment experienced patients in 4Q 2025 and data readout in 1Q 2027. ARTEMIS is the first of two Phase 3 registrational trials for Ixo-vec in wet AMD, evaluating a single administration of Ixo-vec compared to aflibercept every 8 weeks in both treatment-naive and previously treated patients.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADVM:
- Private Markets: Anthropic raises $13B Series F at $183B post-money valuation
- Promising Outlook for Adverum Biotechnologies’ Ixo-vec in Wet AMD Treatment: Buy Rating Affirmed
- Adverum Biotechnologies Faces Financial Challenges Amid Gene Therapy Development
- Adverum Biotechnologies reports Q2 EPS ($2.34), consensus ($2.28)
- Adverum Biotechnologies sees cash runway into 4Q25